Boston Scientific Stock News

Boston Scientific Corporation (NYSE:BSX ) Business Update Earnings Conference Call October 30, 2024 4:00 PM ET Company Participants Jonathan Monson - Senior Vice President of Investor Relations Joseph Fitzgerald - Executive Vice President and Group President, Cardiology Lance Bates - Senior Vice President and President Janar Sathananthan - Chief Medical Officer Kenneth Stein - Chief Medical Off...

Medical devices maker Boston Scientific should continue to grow profitably through the next several years. Backing that bullishness is its history, good margins, pipeline, capital allocation, and more. While all other Seeking Alpha analysts have rated it a Hold this year, I have a Buy rating and expect the price to grow nearly 15% in the coming year.

MARLBOROUGH, Mass. and WASHINGTON , Oct. 30, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated the ACURATE neo2™ Aortic Valve System in the treatment of patients with severe, symptomatic aortic stenosis at low, intermediate, high and extreme risk of open-heart surgery.

Boston Scientific (BSX) shares fell Wednesday when the medical equipment manufacturer's third-quarter profit fell and its GAAP earnings per share (EPS) came in short of its guidance.

Boston Scientific Corporation (NYSE:BSX ) Q3 2024 Earnings Conference Call October 23, 2024 8:00 AM ET Company Participants Jonathan Monson - Senior Vice President, Investor Relations Michael Mahoney - Chairman and Chief Executive Officer Daniel Brennan - Executive Vice President and Chief Financial Officer Kenneth Stein - Senior Vice President, Global Chief Medical Officer Conference Call Part...

Medical-products company Boston Scientific reported third-quarter results before market open.

Boston Scientific raised its annual profit forecast and exceeded Wall Street's estimates for third-quarter profit on Wednesday, driven by robust demand for its heart devices, sending its shares higher 1.1% to $88.94 in premarket trading.

Boston Scientific earnings and sales beat Q3 views early Wednesday. The medtech giant's shares, right at record highs, rose before the open,